Healthy volunteers in first‐in‐human oncology drug development for small molecules

This review provides tools to consider the inclusion of healthy volunteers (HVs) in first‐in‐human (FIH) oncology clinical trials with small molecules, including targeted and immunomodulatory agents, a strategy that was not envisioned with classic chemotherapy. To enable an FIH oncology trial in HVs...

Descripción completa

Detalles Bibliográficos
Autores principales: de las Heras, Begoña, Bouyoucef‐Cherchalli, Dalila, Reeve, Lesley, Reichl, Andreas, Mandarino, Debra, Flach, Stephen, Vidal, Laura, van Brummelen, Emilie M. J., Steeghs, Neeltje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234445/
https://www.ncbi.nlm.nih.gov/pubmed/34558113
http://dx.doi.org/10.1111/bcp.15092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234445/
https://www.ncbi.nlm.nih.gov/pubmed/34558113
http://dx.doi.org/10.1111/bcp.15092

Ejemplares similares